“A healthy volunteer receives the NIAID Zika virus investigational DNA vaccine as part of an early-stage trial to test the vaccine’s safety and immunogenicity. This is the first administration of this vaccine in a human.
“The needle-free technology company announced that the NIH would be using its device in August of this year. Recently, Ron Lowy, chairman and CEO at PharmaJet provided an update on the trial, commenting that the company is encouraged by the positive results.
“’As with many development programs the challenge isn’t that our devices haven’t been proven to work, it is a question as to the effectiveness of the vaccine or therapeutic being studied,’ he told us.
“Lowy explained the next steps are to complete the Phase I and Phase II steps of the trials with the NIH. As Outsourcing-Pharma.com previously reported, the device works by delivering medications and vaccines intradermally via a narrow, high velocity fluid stream, which Lowy said prevents needle-stick injuries, needle re-use, and cross contamination or spread of diseases.
“The device also delivers the vaccine in about 1/10th of a second. ‘Our needle-free device is fast, safe, and easy to use, and in some cases, has been shown to enhance the effectiveness of certain vaccines,’ added Lowy. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched the clinical trial earlier this year.”